logo-loader
viewBed Bath & Beyond Inc.

Bed Bath & Beyond beats on 3Q earnings; shares jump in after-hours trading

The specialty retailer beat Wall Street estimates, posting a third-quarter EPS of $0.18, better than analyst estimates of $0.17

bed bath beyond store
The retailer operates a chain of home goods stores in the US and Canada

Bed Bath & Beyond Inc (NASDAQ:BBBY) shares soared Wednesday in after hours trading after it beat analyst estimates in its fiscal third-quarter results.

Shares were up 16% at US$14.22. 

The home goods specialty retailer beat Wall Street estimates, posting a third-quarter EPS of $0.18, better than analyst estimates of $0.17.

The New Jersey-based company saw its revenue for the quarter come in at $3 billion versus the consensus estimate of $3.04 billion. 

READ: Small-Cap Snapshot: Bed Bath & Beyond shares rise ahead of 3Q earnings

The company said sales in the fiscal 2018 third quarter declined approximately 1.8%. 

Bed Bath & Beyond also announced a quarterly dividend on Wednesday of $0.16 per share payable on April 16, 2019 to shareholders of record at the close of business on March 15, 2019.

During the fiscal 2018 third quarter, the company repurchased approximately $8 million of its common stock, representing approximately 527,000 shares.

"The company is ahead of plan with respect to its longer-term financial goals to moderate the declines in its operating profit and net earnings per diluted share, this year and next, and grow net earnings per diluted share by 2020, and based on its preliminary assumptions, believes that its fiscal 2019 net earnings per diluted share will be about the same as fiscal 2018," said the company in a release. 

The retailer operates a chain of home goods stores in the US and Canada, including namesake Bed Bath and Beyond, buybuy BABY, Christmas Tree Shops and Harmon Face Values.

Quick facts: Bed Bath & Beyond Inc.

Price: 13.5 USD

NASDAQ:BBBY
Market: NASDAQ
Market Cap: $1.71 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Mereo BioPharma CEO confident as it moves forward with pivotal Setrusumab study

Mereo BioPharma's (LON:MPH) Denise Scots-Knight explains why she's confident in the potential of their lead drug setrusumab despite it not meeting its primary endpoint in a recent Phase 2b study. The drug's being developed as a treatment for osteogenesis imperfecta which is also known as...

9 minutes ago

2 min read